Glioblastoma and diffuse astrocytoma, IDH wildtype

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from AbbVie and Novocure for speaking engagements, from Eisai for consulting work, and from Monetris as an advisory board member.

This article includes discussion of diffuse astrocytomas, IDH wildtype, with particular focus on glioblastoma, IDH wildtype, including classification and treatment.

Overview

Diffuse astrocytomas, IDH wildtype, encompass a variety of histologies, with glioblastomas being the most common and most aggressive subtype. This review focuses on diagnosis and management of adult glioblastoma, IDH wildtype, and discusses other histologies included in the 2016 World Health Organization classification of IDH wildtype astrocytoma.

Key points

• Glioblastoma, IDH wildtype, is the most common malignant primary brain tumor with an often aggressive clinical course.

• Age and performance status at diagnosis in glioblastoma may influence optimal dosing of radiation and chemotherapy.

• Molecular testing should be considered in diffuse astrocytomas that are IDH1 R132H wildtype by immunohistochemistry with high clinical or radiologic suspicion for glioblastoma to evaluate hallmark features of molecular glioblastoma.

• Diffuse astrocytomas, IDH wildtype, also include diffuse midline gliomas with H3 K27 mutation, pleomorphic xanthoastrocytomas, and others and are defined by other molecular signatures and are not discussed in detail in this review.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.